Syndax Pharmaceuticals (SNDX) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 3 Phase 2[2], 2 Phase 1[3].
Trial NCT07211958[5] evaluates Revumenib in Acute Myeloid Leukemias with a target enrollment of 468 participants.
No Form 4 insider filings for SNDX were recorded at the SEC in the past 30 days[6].